The EP3-agonist sulprostone, but not prosta glandin E 2 potentiates platelet aggregation in human blood

Thrombosis and Haemostasis

Volumn 103, Issue 6, 2010, Pages 1268-1269

  Schober, Lisa J ^a   Khandoga, Anna L ^a   Penz, Sandra M ^a   Siess, Wolfgang ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; COLLAGEN; HIRUDIN; PROSTAGLANDIN E2; SULPROSTONE; CITRIC ACID; DRUG DERIVATIVE; HIRUDIN DERIVATIVE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN EP3 RECEPTOR; VASOCONSTRICTOR AGENT;

CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN TISSUE; LETTER; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECT; INFLAMMATION; METABOLISM; PATHOLOGY; THROMBOCYTE;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADENOSINE DIPHOSPHATE; BLOOD PLATELETS; CELLS, CULTURED; CITRATES; COLLAGEN; DINOPROSTONE; DRUG SYNERGISM; HIRUDINS; HUMANS; INFLAMMATION; PLATELET AGGREGATION; RECEPTORS, PROSTAGLANDIN E; VASOCONSTRICTOR AGENTS;

EID: 77953152278     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-12-0815     Document Type: Letter

References (19)

1. Matsumoto H, Naraba H, Murakami M, et al. Concordant induction of prostaglandin E2 synthase with cyclooxygenase-2 leads to preferred production of prostaglandin E2 over thromboxane and prostaglandin D2 in lipopolysaccharide- stimulated rat peritoneal macrophages. Biochem Biophys Res Commun 1997; 230: 110-114.
2. Rouzer CA, Scott WA, Hamill AL, et al. Secretion of leukotriene C and other arachidonic acid metabolites by macrophages challenged with immunoglobulin E immune complexes. J Exp Med 1982; 156: 1077-1086.
3. Brock TG, McNish RW, Peters-Golden M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem 1999; 274: 11660-11666. (Pubitemid 129518418)
4. Gross S, Tilly P, Hentsch D, et al. Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J Exp Med 2007; 204: 311-320.
5. Paul BZ, Ashby B, Sheth SB. Distribution of prostaglandin IP and EP receptor subtypes and isoforms in platelets and human umbilical artery smooth muscle cells. Br J Haematol 1998; 102: 1204-1211.
6. Fabre JE, Nguyen M, Athirakul K, et al. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest 2001; 107: 603-610. (Pubitemid 32205181)
7. Ma H, Hara A, Xiao CY, et al. Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E receptor subtype EP(3). Circulation 2001; 104: 1176-1180.
8. Matthews JS, Jones RL. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues. Br J Pharmacol 1993; 108: 363-369.
9. Vezza R, Roberti R, Nenci GG, et al. Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C. Blood 1993; 82: 2704-2713. (Pubitemid 23318076)
10. Heptinstall S, Espinosa DI, Manolopoulos P, et al. DG-041 inhibits the EP3 prostanoid receptor - a new target for inhibition of platelet function in atherothrombotic disease. Platelets 2008; 19: 605-613.
11. Salzman EW, Kensler PC, Levine L. Cyclic 3′,5′-adenosine monophosphate in human blood platelets. IV. Regulatory role of cyclic amp in platelet function. Ann NY Acad Sci 1972; 201: 61-71.
12. Weiss HJ, Willis AL, Kuhn D, et al. Prostaglandin E2 potentiation of platelet aggregation induced by LASS endoperoxide: absent in storage pool disease, normal after aspirin ingestion. Br J Haematol 1976; 32: 257-272.
13. MacIntyre DE, Gordon JL. Calcium-dependent stimulation of platelet aggregation by PGE. Nature 1975; 258: 337-339.
14. Gray SJ, Heptinstall S. The effects of PGE2 and CL 115,347, an antihypertensive PGE2 analogue, on human blood platelet behaviour and vascular contractility. Eur J Pharmacol 1985; 114: 129-137.
15. Toth O, Calatzis A, Penz S, et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
16. Awidi A, Maqablah A, Dweik M, et al. Comparison of platelet aggregation using light transmission and multiple electrode aggregometry in Glanzmann thrombasthenia. Platelets 2009; 20: 297-301.
17. Penz SM, Reininger AJ, Toth O, et al. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Thromb Haemost 2007; 97: 435-443.
18. Breyer RM, Bagdassarian CK, Myers SA, et al. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-690.
19. Israel DD, Regan JW. EP(3) prostanoid receptor isoforms utilize distinct mechanisms to regulate ERK 1/2 activation. Biochim Biophys Acta 2009; 1791: 238-245.